Differences found in lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using FRI.

This study will be presented at ERS 2019 at a thematic poster session on Monday September 30 between 12.50 pm and 2.40 pm.

Functional Respiratory Imaging evaluated lung deposition patterns of extrafine ICS/LABA/LAMA with a pressurized metered dose inhaler (pMDI) and non-extrafine ICS/LABA/LAMA with a dry powder inhaler (DPI), in patients with stable COPD and moderate to very severe airflow obstruction.

FRI data indicated a higher peripheral lung (small airways) deposition with extrafine triple therapy than with non-extrafine. This may be attributed to the lower Mass Median Aerodynamic Diameter (MMAD) of the extrafine formulation.

Sorry, comments are closed for this post.